Kernel Founder/CEO Bryan Johnson wearing Flow during the Ketamine pilot study. Nasal cannula is part of the study and not required or part of Flow.
Cybin and Kernel Announce Results from Kernel Flow® Piloting of Feasibility Study Measuring Ketamine’s Effects on the Brain
Preliminary data confirm Flow's ability to successfully measure neuro-effect of ketamine over 10 days reports Kernel.